MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock, common...
$101,345K
Proceeds from the espp
purchase
$304K
Net cash and cash
equivalents provided by...
$101,635K
Canceled cashflow
$14K
Net decrease in
cash, cash...
-$18,694K
Canceled cashflow
$101,635K
Stock-based compensation
including espp
$5,044K
Non cash lease
expense
$1,875K
Accounts payable
$1,411K
Depreciation expense
$930K
Other assets
-$96K
Maturities of short-term
investments
$127,500K
Payments on finance lease
$14K
Net cash and cash
equivalents used in...
-$82,503K
Canceled cashflow
$9,356K
Net cash and cash
equivalents used in...
-$37,826K
Canceled cashflow
$127,500K
Change in fair value of
2023 common warrants
-$60,184K
Net loss
-$24,193K
Operating lease
liabilities
-$3,112K
Accretion of discount on
investments
$2,188K
Accrued liabilities
-$2,031K
Deferred revenue
-$151K
Purchase of short-term
investments
$164,889K
Purchases of property and
equipment
-$437K
Back
Back
Cash Flow
source: myfinsight.com
Aligos Therapeutics, Inc. (ALGS)
Aligos Therapeutics, Inc. (ALGS)